Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease

Next Previous
Search
Trial Profile

Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANPD 001 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man
  • Acronyms ASPERO; ASPIRO
  • Sponsors Aspen Neuroscience

    • Most Recent Events

    • 13 Jan 2025 According to an Aspen Neuroscience media release, company has announced that they have successfully completed dose escalation and the first two cohorts of patients in this trial
    • 07 Oct 2024 According to an Aspen Neuroscience media release, announced it has completed dosing of the first cohort of patients in the ASPIRO Phase 1/2a clinical trial of ANPD001.
    • 01 Oct 2024 According to an Aspen Neuroscience media release, the company announced the expansion of its San Diego footprint near its headquarters in Torrey Pines, for GMP manufacturing of induced pluripotent stem cell (iPSC)-derived cell therapies and the company will use the cells in its ASPIRO study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top